Jeremy Curnock Cook, Chairman of the Board
Mr. Cook has served as a director of Targeted Genetics since July 1995 and as chairman of the board since February 1998. Mr. Cook founded the International Biochemicals Group in 1975, which was sold to Royal Dutch Shell in 1985, serving as managing director until 1987. From 1987 to 2000, he was a director of Rothschild Asset Management Limited and was responsible for the Rothschild Bioscience Unit. He currently serves as chairman of the board of International Bioscience Managers Ltd. and as a director of SIRNA Therapeutics Inc., Inflazyme Pharmaceuticals, Ltd. and several public and privately held companies outside the United States. Mr. Cook previously served as a director of Cell Therapeutics, Inc. and Creative BioMolecules, Inc. Mr. Cook received his M.A. in Natural Sciences from Trinity College, Dublin.
Jack L. Bowman
Mr. Bowman has served as a director of Targeted Genetics since March 1997. From March 2003 to May 2004, Mr. Bowman served as executive chairman and chairman of the board of NeoRx Corporation, a cancer therapeutics development company, and as its chief executive officer from June 2003 to May 2004. From 1987 to January 1994, Mr. Bowman was a company group chairman at Johnson & Johnson, with primary responsibility for a group of companies in the diagnostic, blood glucose monitoring and pharmaceutical businesses. From 1980 to 1987, he held various positions at American Cyanamid Company, a pharmaceutical company, most recently as executive vice president. Mr. Bowman previously served as a member of the board of trustees of The Johns Hopkins University and NeoRx Corporation and currently serves as a director of Celgene Corporation and AVI Biotherapeutics, Inc.
Joseph M. Davie, M.D., Ph.D.
Dr. Davie has served as a director of Targeted Genetics since October 2000. Dr. Davie was employed by Biogen, Inc., a biopharmaceutical company, from 1993 to 2000, most recently serving as senior vice president, research. From 1987 to 1993, Dr. Davie held several positions at G.D. Searle & Co., including president of research and development and senior vice president of science and technology. Dr. Davie was professor and head of the Department of Microbiology and Immunology at Washington University School of Medicine from 1975 to 1987. He currently serves as a director of Curis, Inc., Inflazyme Pharmaceuticals, Ltd. and several privately held companies. Dr. Davie received his A.B., M.A. and Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine.
Roger L. Hawley
Mr. Hawley has served as a director of Targeted Genetics since August 2005. In July 2003, he joined InterMune, a biopharmaceutical company focused on therapies in hepatology and pulmonology and currently serves as Executive Vice President, Commercial and Technical Operations. Prior to joining InterMune, Mr. Hawley served as Chief Commercial Officer at Prometheus Laboratories, Inc., a specialty pharmaceutical company, from October 2002 to July 2003. From 2001 to 2002, Mr. Hawley served as General Manager & Vice President of Sales and Marketing at Elan Pharmaceuticals, Inc. From 1987 to 2001, Mr. Hawley held a broad range of management positions in commercial operations, alliance/partnership management, regional sales and corporate finance at GlaxoSmithKline (GSK), one of the world’s largest pharmaceutical companies. His most recent position at GSK was Vice President of Sales-CNS/GI Division. Prior to joining GSK in treasury management, he held various financial management positions from 1976 to 1987 with Marathon Oil Company, including serving four years in London, England. While at Marathon he was a certified treasury manager and a certified public accountant. Mr. Hawley holds a B.S. in accounting from Eastern Illinois University.
Louis P. Lacasse
Mr. Lacasse has served as a director of Targeted Genetics since May 1998. Mr. Lacasse has served as president of GeneChem Management, Inc. and as manager of GeneChem Technologies Venture Fund L.P. and GeneChem Theraputics Venture Fund, L.P., two venture capital funds, since May 1997. He served as vice president (Healthcare and Biotechnology) of SOFINOV, an investment subsidiary of Caisse de depot et placement du Quebec, from July 1987 to May 1997. Mr. Lacasse previously served as a director of several private and public companies, including Biochem Pharma Inc. and Axcan Pharma, Inc., and currently serves as a director of several privately held biotechnology companies. Mr. Lacasse received his Bachelor’s degree from the École des Hautes Études Commerciales and his M.B.A. from McGill University.
Nelson L. Levy, M.D., Ph.D.
Dr. Levy has served as a director of Targeted Genetics since May 1999. Since 1993, Dr. Levy has served as chairman of the board and chief executive officer of CoreTechs Corporation, a privately held company that focuses on the development and marketing of early-stage technologies. He served as president of Fujisawa Pharmaceutical Company, the U.S. subsidiary of Japan’s third-largest pharmaceutical company, from 1992 to 1993, as chief executive officer of CoreTechs from 1984 to 1992 and as vice president for pharmaceutical research at Abbott Laboratories from 1981 to 1984. Dr. Levy served as a tenured professor of microbiology and immunology at Duke University from 1970 to 1981. He currently serves as a director of several privately held companies and on the scientific advisory boards of several public and privately held biotechnology and pharmaceutical companies. Dr. Levy received his B.A. from Yale University, his M.D. from Columbia University and his Ph.D. from Duke University.
H. Stewart Parker
Ms. Parker managed the formation of Targeted Genetics as a wholly owned subsidiary of Immunex Corporation (Immunex was subsequently acquired by Amgen) and has served as president, chief executive officer and a director of Targeted Genetics since our spinout of Immunex in 1992. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. She serves on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several privately held companies. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Michael Perry, D.V.M., Ph.D.
Dr. Perry has served as a director of Targeted Genetics since November 2005. Dr. Perry is the Chief Development Officer for VIA Pharmaceuticals. Prior to joining VIA, Dr. Perry co-founded Extropy Pharmaceuticals, Inc., a pediatric specialty pharmaceutical company. Dr. Perry was Chairman and Chief Executive Officer of Extropy from June 2003 to March 2005. From February 2002 to March 2003, Dr. Perry was President and Chief Executive Officer of Pharsight Corp., a publicly traded software and consulting services firm integrating scientific and business decision criteria in computer-based models for optimizing drug development. From October 2000 to February 2002, Dr. Perry was Worldwide Head, Global R&D at Baxter BioScience, with responsibility for the company’s R&D organization, from basic discovery through product launch and life cycle management. From 1994 to 2000, Dr. Perry was an executive with Sandoz / Novartis Pharma, where his responsibilities included global regulatory affairs and drug registration. He also was President and Chief Executive Officer of two wholly owned Novartis biotech subsidiaries, SyStemix Inc. and Genetic Therapy Inc. Prior to joining Sandoz / Novartis, Dr. Perry held executive positions in regulatory affairs with Syntex Corp. and Schering-Plough Corp. Previously, he held management positions with BioResearch Laboratories, Inc., a contract research organization, and also practiced veterinary medicine. Dr. Perry received his BSc (Hon.) degree in Physics and his DVM degree from the University of Guelph. He also earned his PhD in Biomedical Science, with a specialty in Cardiopulmonary Pharmacology, from the University of Guelph. From 1997 to 1998 Dr. Perry was sponsored by Novartis in the Executive Management Program at Harvard University. He is a Fellow of the American College of Veterinary Pharmacology and Therapeutics.
|
